DE602005023646D1 - Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung - Google Patents

Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung

Info

Publication number
DE602005023646D1
DE602005023646D1 DE602005023646T DE602005023646T DE602005023646D1 DE 602005023646 D1 DE602005023646 D1 DE 602005023646D1 DE 602005023646 T DE602005023646 T DE 602005023646T DE 602005023646 T DE602005023646 T DE 602005023646T DE 602005023646 D1 DE602005023646 D1 DE 602005023646D1
Authority
DE
Germany
Prior art keywords
cancer
neoplasia
maligner
taxan
forecasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005023646T
Other languages
English (en)
Inventor
Udo Stropp
Marc Munnes
Ralph M Wirtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Siemens Healthcare Diagnostics GmbH Germany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics GmbH Germany filed Critical Siemens Healthcare Diagnostics GmbH Germany
Publication of DE602005023646D1 publication Critical patent/DE602005023646D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
DE602005023646T 2004-12-10 2005-12-08 Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung Active DE602005023646D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029323 2004-12-10
PCT/EP2005/013141 WO2006061216A2 (en) 2004-12-10 2005-12-08 Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment

Publications (1)

Publication Number Publication Date
DE602005023646D1 true DE602005023646D1 (de) 2010-10-28

Family

ID=34927727

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005023646T Active DE602005023646D1 (de) 2004-12-10 2005-12-08 Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung

Country Status (6)

Country Link
US (1) US20090215036A1 (de)
EP (1) EP1824997B1 (de)
JP (1) JP2008524986A (de)
AT (1) ATE481504T1 (de)
DE (1) DE602005023646D1 (de)
WO (1) WO2006061216A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2445204C (en) 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
EP1954837A4 (de) * 2005-11-28 2009-11-04 Siemens Healthcare Diagnostics Kinetischer pcr-test zur quantifizierung der genamplifikation auf chromosom 17
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US20110136123A1 (en) * 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
FR2928657B1 (fr) * 2008-03-14 2013-12-20 Chu Saint Etienne Chu Hopital Nord Methode, procede, et kit de diagnostic, pronostic, suivi d'un cancer
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE202010018569U1 (de) 2009-02-18 2017-09-26 Streck Inc. Konservierung zellfreier Nukleinsäuren
JP2013510580A (ja) * 2009-11-12 2013-03-28 エソテリックス ジェネティック ラボラトリーズ， エルエルシー 遺伝子座のコピー数の分析
JP5497423B2 (ja) * 2009-12-25 2014-05-21 東京エレクトロン株式会社 成膜装置
EP2663652B1 (de) 2011-01-11 2018-11-14 Roche Diagniostics GmbH Schmelzanalyse mit hoher auflösung als voruntersuchungsinstrument
PL2768985T3 (pl) * 2011-10-21 2019-10-31 Chronix Biomedical Biomarkery będące krążącymi kwasami nukleinowymi związane z rakiem jelita grubego
DK2814981T3 (en) * 2012-02-13 2017-10-16 Streck Inc BLOOD COLLECTION UNIT FOR STABILIZING CELL-FREE PLASMA DNA
WO2015013244A1 (en) 2013-07-24 2015-01-29 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
KR102004335B1 (ko) 2013-09-26 2019-07-26 파이브3 제노믹스, 엘엘씨 바이러스-연관 종양을 위한 시스템, 방법, 및 조성물
EP3143156B1 (de) * 2014-05-12 2020-11-04 Janssen Pharmaceutica NV Biologische marker zur identifikation von patienten zur behandlung mit abirateronacetat
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
CN108026589B (zh) 2015-09-24 2022-09-06 株式会社益力多本社 治疗方法的选择方法以及表明该选择方法的生物标志
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2017165803A1 (en) * 2016-03-24 2017-09-28 President And Fellows Of Harvard College Compositions and methods that are useful for identifying allele variants that modulate gene expression
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
KR102016216B1 (ko) * 2017-09-29 2019-08-29 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이의 용도
AU2019301944B2 (en) 2018-07-10 2022-02-24 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1900827A3 (de) * 2002-05-21 2008-04-16 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien

Also Published As

Publication number Publication date
EP1824997A2 (de) 2007-08-29
JP2008524986A (ja) 2008-07-17
ATE481504T1 (de) 2010-10-15
WO2006061216A2 (en) 2006-06-15
EP1824997B1 (de) 2010-09-15
US20090215036A1 (en) 2009-08-27
WO2006061216A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
DE602005023646D1 (de) Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
ATE550440T1 (de) Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
Lin et al. Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance
Fellenberg et al. Prognostic significance of drug-regulated genes in high-grade osteosarcoma
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
DE602005007623D1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
NO20074104L (no) Fremgangsmater og systemer for diagnose, prognose og seleksjon ved behandling av leukemi
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
Zhang et al. MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4
NO20081307L (no) RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
EP2558598A4 (de) Biomarker auf basis eines mit einer mehrfachkarzinom-invasion assoziierten mechanismus
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
NO20090174L (no) Genfamilie (LBFL313) assosiert med kreft i bukspyttkjertel
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
Zhou et al. Prognostic value of microRNA-100 in esophageal squamous cell carcinoma
MX2012003329A (es) Metodo para identificar si un paciente respondera o no a la inmunoterapia.
EP1568383A3 (de) Verwendung eines Oligonukleotide oder seiner aktiven Ableitung für die Zubereitung einer pharmazeutische Zusammensetzung zur Hemmung der Metastasenbildung in Krebsbehandlung